{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T08:56:43Z","timestamp":1649062603574},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1986,2,1]],"date-time":"1986-02-01T00:00:00Z","timestamp":507600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutisch Weekblad Scientific Edition"],"published-print":{"date-parts":[[1986,2]]},"DOI":"10.1007\/bf01975480","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T08:56:30Z","timestamp":1123059390000},"page":"46-52","source":"Crossref","is-referenced-by-count":6,"title":["New 4-quinolones in the treatment of urinary tract infections"],"prefix":"10.1007","volume":"8","author":[{"given":"J. B. J.","family":"Boerema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01975480_CR1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJM196611172752001","volume":"275","author":"AR Roland","year":"1966","unstructured":"Roland AR, Turck M, Petersdorf RG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med 1966;275:1081\u20133.","journal-title":"N Engl J Med"},{"key":"BF01975480_CR2","first-page":"299","volume":"233","author":"JT Smith","year":"1984","unstructured":"Smith JT. Awaking the slumbering potential of the 4-quinolone antibacterials. Pharm J 1984;233:299\u2013305.","journal-title":"Pharm J"},{"key":"BF01975480_CR3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.1976.03270170023019","volume":"236","author":"TA Stamey","year":"1976","unstructured":"Stamey TA, Bragonje J. Resistance to Nalidixic Acid. A misconception due to underdosage. JAMA 1976;236:1857\u201360.","journal-title":"JAMA"},{"key":"BF01975480_CR4","first-page":"169","volume":"38","author":"P Turgeon","year":"1985","unstructured":"Turgeon P, Dubois J, Stoffel S.In vitro activity of norfloxacin against 4003 clinical isolates: a multicentre study in Canada. Curr Ther Res 1985;38:169\u201372.","journal-title":"Curr Ther Res"},{"key":"BF01975480_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02001575","volume":"2","author":"A Bauernfeind","year":"1983","unstructured":"Bauernfeind A, Peterm\u00fcller C.In vitro activity of ciprofloxacin. norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983;2:111\u20135.","journal-title":"Eur J Clin Microbiol"},{"key":"BF01975480_CR6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.25.5.633","volume":"25","author":"AL Barry","year":"1984","unstructured":"Barry AL, Jones RN, Thornsberry C, Avers LW, Gerlach EH, Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin. oxolinic acid. cinoxacin. and nalidixic acid. Antimicrob Agents Chemother 1984;25:633\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR7","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.24.4.568","volume":"24","author":"RJ Fass","year":"1983","unstructured":"Fass RJ.In vitro activity of ciprofloxacin (Bay 09867). Antimicrob Agents Chemother 1983;24:568\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1128\/AAC.23.4.559","volume":"23","author":"R Wise","year":"1983","unstructured":"Wise R, Andrews JM, Edwards LJ.In vitro activity of Bay 09867. a new quinoline derivative compared with those of other antimicrobial agents. Antimicrob Agents Chemother 1983;23:559\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/13.4.333","volume":"13","author":"DS Reeves","year":"1984","unstructured":"Reeves DS, Bijwater MJ, Holt HA, White LO.In vitro studies with ciprofloxacin. a new 4-quinolone compound. J Antimicrob Chemother 1984;13:333\u201346.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jac\/13.4.325","volume":"13","author":"A King","year":"1984","unstructured":"King A, Shannon K, Phillips I. Thein vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother 1984;13:325\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/17.1.69","volume":"17","author":"FThC Willems","year":"1986","unstructured":"Willems FThC, Boerema JBJ, Van Summeren TRKM. Thein vitro comparative activity of quinolones against bacteria from urinary tract infections in general practice. J Antimicrob Chemother 1986;17:69\u201373.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/15.1.39","volume":"15","author":"AM Clarke","year":"1985","unstructured":"Clarke AM, Zemcov SJV, Campbell ME.In vitro activity of pefloxacin compared to enoxacin. norfloxacin. gentamicin and new \u03b2-lactams. J Antimicrob Chemother 1985;15:39\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF02013582","volume":"4","author":"AF Kent","year":"1985","unstructured":"Kent AF, Speller DCE. Sensitivity of urinaryStaphylococci to ciprofloxacin and acrosoxacin. Eur J Clin Microbiol 1985;4:139\u201340.","journal-title":"Eur J Clin Microbiol"},{"key":"BF01975480_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.28.4.581","volume":"28","author":"JS Wolfson","year":"1985","unstructured":"Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activityin vitro. Antimicrob Agents Chemother 1985;28:581\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.28.5.716","volume":"28","author":"DC Hooper","year":"1985","unstructured":"Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicity in humans. Antimicrob Agents Chemother 1985;28:716\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2165\/00003495-198530060-00003","volume":"30","author":"B Holmes","year":"1985","unstructured":"Holmes B, Brogden RN, Richards DM. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985;30:482\u2013513.","journal-title":"Drugs"},{"key":"BF01975480_CR17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01645218","volume":"12","author":"MS Sabbour","year":"1984","unstructured":"Sabbour MS, El Blokl MA, Osman LM. Experiences on the efficacy and safety of nalidixic acid. oxolonic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI). Infection 1984;12:377\u201380.","journal-title":"Infection"},{"key":"BF01975480_CR18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/15.4.505","volume":"15","author":"S Hill","year":"1985","unstructured":"Hill S, Yeates M, Pathy J, Morgan JRS. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly. J Antimicrob Chemother 1985;15:505\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl B","key":"BF01975480_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jac\/13.suppl_B.89","volume":"13","author":"B Watt","year":"1984","unstructured":"Watt B, Chait I, Kelsey MC. et al. Norfloxacin versus co-trimoxazole in the treatment of uncomplicated urinary tract infections \u2014 a multicentre trial. J Antimicrob Chemother 1984;13(suppl B):89\u201394.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl B","key":"BF01975480_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/13.suppl_B.107","volume":"13","author":"CP Kirby","year":"1984","unstructured":"Kirby CP. Treatment of simple urinary tract infection in general practice with a 3-day course of norfloxacin. J Antimicrob Chemother 1984;13(suppl B):107\u201312.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl B","key":"BF01975480_CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/13.suppl_B.113","volume":"13","author":"R Vogel","year":"1984","unstructured":"Vogel R, Deany NB, Round EM, Van den Burg MJ, Currie WJC. Norfloxacin, amoxycillin, co-trimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. J Antimicrob Chemother 1984;13(suppl B):113\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl B","key":"BF01975480_CR22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jac\/13.suppl_B.99","volume":"13","author":"DS Reeves","year":"1984","unstructured":"Reeves DS, Lacey RW, Mummery RV, Mahendra M, Bint AJ, Newson SWB. Treatment of acute urinary tract infection by norfloxacin or nalidixic acid\/citrate: a multicentre comparative study. J Antimicrob Chemother 1984;13(suppl B):99\u2013105.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1128\/AAC.27.3.422","volume":"27","author":"EJC Goldstein","year":"1985","unstructured":"Goldstein EJC, Alpert ML, Ginsberg BP. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother 1985;27:422\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/AAC.27.3.297","volume":"27","author":"J Sabbaj","year":"1985","unstructured":"Sabbaj J, Hoagland VL, Shih WJ. Multiclinical comparative study of norfloxacin and trimethoprim-sulfame-thoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother 1985;27:297\u2013301.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF01975480_CR25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/16.2.211","volume":"16","author":"J Boerema","year":"1985","unstructured":"Boerema J, Boll B, Muytjens H, Branolte J. Efficacy and safety of ciprofloxacin (Bay 09867) in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1985;16:211\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR26","unstructured":"Boerema JBJ, Verheggen W, Branolte J. Comparative efficacy and safety of ciprofloxacin and co-trimoxazole in the treatment of patients with complicated urinary tract infections. Eur J Clinical Microbiol (in press)."},{"key":"BF01975480_CR27","doi-asserted-by":"crossref","unstructured":"Boerema JBJ, Pouwels R. Scheepers J. Crombach W. Efficacy and safety of pefloxacin in the treatment of urinary tract infections. J Antimicrob Chemother (in press).","DOI":"10.1093\/jac\/17.suppl_B.103"},{"key":"BF01975480_CR28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/infdis\/138.6.791","volume":"138","author":"G Wallmark","year":"1978","unstructured":"Wallmark G, Arremark I, Telander B.Stuphylococcus saprophylicus a frequent cause of acute urinary tract infection among female outpatients. J Infect Dis 1978;138:791\u20137.","journal-title":"J Infect Dis"},{"key":"BF01975480_CR29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0022-5347(17)56541-6","volume":"122","author":"B Hovelius","year":"1979","unstructured":"Hovelius B, Mardh PA, Bygren P. Urinary tract infections caused byStaphylococcus saprophylicus: recurrences and complications. J Urol 1979;122:645\u2013746.","journal-title":"J Urol"},{"key":"BF01975480_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0090-4295(84)90136-5","volume":"13","author":"RI Lewis","year":"1984","unstructured":"Lewis RI, Carrion HM, Lockhart JI, Politano VA. Significance of asymptomatic bacteriuria in neurogenic bladder disease. Urology 1984;13:343\u20137.","journal-title":"Urology"},{"issue":"suppl B","key":"BF01975480_CR31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/13.suppl_B.85","volume":"13","author":"DA Leigh","year":"1984","unstructured":"Leigh DA, Emmanuel FXSD. The treatment ofPseudomonas aeruginosa urinary tract infections with norfloxacin. J Antimicrob Chemother 1984;13(suppl B):85\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR32","unstructured":"Boerema JBJ. Long-term treatment of complicated UTI with norfloxacin. 4th Mediterranean Congress of Chemotherapy. Rhodos. October 19\u201325, 1984."},{"key":"BF01975480_CR33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/219139a0","volume":"219","author":"DG Winningham","year":"1968","unstructured":"Winningham DG, Nemoy NJ, Stamey TA. Diffusion of antibiotics from plasma into prostatic fluid. Nature 1968;219:139\u201342.","journal-title":"Nature"},{"key":"BF01975480_CR34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000238308","volume":"31","author":"JBJ Boerema","year":"1985","unstructured":"Boerema JBJ, Dahlhoff A, Debruyne FMJ. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985;31:13\u20138.","journal-title":"Chemotherapy"},{"key":"BF01975480_CR35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(84)91252-2","volume":"2","author":"JBJ Boerema","year":"1984","unstructured":"Boerema JBJ, Debruyne FMJ, Dahlhoff A. Intraprostatic concentrations of ciprofloxacin after intravenous administration. Lancet 1984;2:695\u20136.","journal-title":"Lancet"},{"key":"BF01975480_CR36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(83)90258-1","volume":"2","author":"M Bologna","year":"1983","unstructured":"Bologna M, Vaggi L, Forchetti CM, Martini E. Bactericidal intra-prostatic concentrations of norfloxacin. Lancet 1983;2:280.","journal-title":"Lancet"},{"key":"BF01975480_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(85)90083-2","volume":"2","author":"ST Chapman","year":"1985","unstructured":"Chapman ST, Speller DCE, Reeves DS. Resistance to ciprofloxacin. Lancet 1985;2:39.","journal-title":"Lancet"},{"key":"BF01975480_CR38","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(85)92510-3","volume":"2","author":"H Humphreys","year":"1985","unstructured":"Humphreys H, Mulvihill E. Ciprofloxacin-resistantStaphylococcus aureus. Lancet 1985;2:383.","journal-title":"Lancet"},{"key":"BF01975480_CR39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(85)90880-3","volume":"2","author":"GM Smith","year":"1985","unstructured":"Smith GM, Cashmore C, Leyland MJ. Ciprofloxacin-resistantStaphylococci. Lancet 1985;2:949.","journal-title":"Lancet"},{"key":"BF01975480_CR40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01977492","volume":"3","author":"JT Smith","year":"1984","unstructured":"Smith JT. Mutational resistance to 4-quinolones antibacterial agents. Eur J Clin Microb 1984;3:347\u201350.","journal-title":"Eur J Clin Microb"},{"key":"BF01975480_CR41","first-page":"446","volume":"96","author":"RR Bailey","year":"1983","unstructured":"Bailey RR, Peddie BA, Blake E. Norfloxacin for the treatment of uncomplicated urinary tract infections. NZ Med J 1983;96:446.","journal-title":"NZ Med J"},{"key":"BF01975480_CR42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02029529","volume":"2","author":"JG Guerra","year":"1983","unstructured":"Guerra JG, Falconi E, Palomino JC, Benavente L, Antunez de Mayolo E. Clinical evaluation of norfloxacin versus co-trimoxazole in urinary tract infections. Eur J Clin Microbiol 1983;2:260\u20135.","journal-title":"Eur J Clin Microbiol"},{"key":"BF01975480_CR43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF02029530","volume":"2","author":"H Giamarellou","year":"1983","unstructured":"Giamarellou H, Tsagarakis J, Petrikkos G, Daikos GK. Norfloxacin versus co-trimoxazole infections. Eur J Clin Microbiol 1983;2:266\u20139.","journal-title":"Eur J Clin Microbiol"},{"issue":"suppl B","key":"BF01975480_CR44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/13.suppl_B.121","volume":"13","author":"W Brumfitt","year":"1984","unstructured":"Brumfitt W, Hamilton-Miller JMT. A review of the problem of urinary infection management and the evaluation of a potential new antibiotic. J Antimicrob Chemother 1984;13(suppl B):121\u201333.","journal-title":"J Antimicrob Chemother"},{"issue":"suppl B","key":"BF01975480_CR45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/13.suppl_B.79","volume":"13","author":"DA Leigh","year":"1984","unstructured":"Leigh DA, Smith EC, Marriner J. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients. J Antimicrob Chemother 1984;13(suppl B):79\u201383.","journal-title":"J Antimicrob Chemother"},{"key":"BF01975480_CR46","first-page":"759","volume":"3\u20135","author":"D Sauerwein","year":"1984","unstructured":"Sauerwein D, Bauernfeind A. Klinische Erfahrungen bei Behandlung von Harnwegsinfekten bei Querschnittgel\u00e4mtem mit Norfloxacin. Fortschr Antimikrob Antineoplast Chemother 1984;3\u20135:759\u201364.","journal-title":"Fortschr Antimikrob Antineoplast Chemother"},{"key":"BF01975480_CR47","first-page":"31","volume":"3","author":"Y Kummoto","year":"1983","unstructured":"Kummoto Y, Ishigami J. Clinical experience with norfloxacin in urinary tract infections. Eur J Chemother Antibiot 1983;3:31\u20139.","journal-title":"Eur J Chemother Antibiot"},{"key":"BF01975480_CR48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1128\/AAC.28.5.700","volume":"28","author":"J Weisser","year":"1985","unstructured":"Weisser J, Wiedemann B. Elimination of plasmids by new 4-quinolones. J Antimicrob Chemother 1985;28:700\u20132.","journal-title":"J Antimicrob Chemother"}],"container-title":["Pharmaceutisch Weekblad Scientific Edition"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01975480.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01975480\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01975480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T14:30:58Z","timestamp":1557757858000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01975480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1986,2]]}},"alternative-id":["BF01975480"],"URL":"https:\/\/doi.org\/10.1007\/bf01975480","relation":{},"ISSN":["0167-6555","1573-739X"],"issn-type":[{"value":"0167-6555","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,2]]}}}